04:46
DecisionDx®-Melanoma Provides the Future of Melanoma Prognosis for Patient, Today
01:08
The DecisionDx®-Melanoma Test Complements Current Melanoma Staging
01:08
The Limitations of Traditional Approaches
01:13
Molecular Prognostic Tests are Changing Management of Dermatologic Cancers
01:07
SLNB Surgical Procedures: Improving Patient Selection
01:27
More Accurately Predicting Individual Risk of Recurrence or Metastasis
01:43
Castle Biosciences: The Skin Cancer Diagnostics Company
06:22
Castle Biosciences: Changing the Way Dermatologic Cancers are Treated and Managed
01:52
The Data that Supports the DecisionDx®-Melanoma Test is Strong
01:16
DecisionDx®-Melanoma Increases the Risk Prediction that is Currently Available for Patients
00:55
DecisionDx®-Melanoma Helps to Guide Patient Management Decisions
X
About
Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. We aim to transform disease management by keeping people first — the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors.
Our innovative tests for skin cancers, uveal melanoma, and Barrett’s esophagus provide personalized, clinically actionable information to clinicians and patients to guide treatment decisions and improve health outcomes. Please visit us at castletestinfo.com/ to learn more about our portfolio of innovative prognostic and diagnostic tests.
Tags